Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca wins USFDA...

    AstraZeneca wins USFDA Approva; for lymphoma drug

    Written by supriya kashyap kashyap Published On 2017-11-01T11:36:43+05:30  |  Updated On 1 Nov 2017 11:36 AM IST
    AstraZeneca wins USFDA Approva; for lymphoma drug

    U.S. regulators have approved a new treatment for people with a rare form of non-Hodgkin lymphoma.


    The Food and Drug Administration granted accelerated approval to AstraZeneca PLC's Calquence for people with mantle cell lymphoma after chemotherapy or other treatments fail. The British drugmaker is now conducting further testing required by the FDA to confirm the drug's benefits and risks.


    Mantle cell lymphoma is a blood cancer that usually strikes middle-aged people and the elderly. By the time it's diagnosed, it usually has spread to the lymph nodes, bone marrow and other organs, according to the FDA.


    About 4,200 Americans are diagnosed with cancer each year. Median survival is about five to seven years, according to the Leukemia and Lymphoma Society. But treatment has been improving in recent years with the addition of targeted drugs and stem cell therapy to chemotherapy.


    "Mantle cell lymphoma is a particularly aggressive cancer," Dr. Richard Pazdur, director of the FDA's oncology center of excellence, said in a statement.


    Calquence, also known as acalabrutinib, works by blocking an enzyme needed by the cancer to multiply and spread.


    Patients take two capsules a day. The drug will cost about $14,260 per month without insurance, according to AstraZeneca.


    The drugmaker said it will offer patients financial assistance, including copayment cards that it said will cover out-of-pocket costs for some patients.


    The FDA based its approval on a company-sponsored study of 124 patients who had received at least one prior treatment. After taking Calquence, 40 percent went into remission and another 41 percent saw their tumors shrink, the agency said.


    The study did not include a comparison group, as is standard in bigger studies.


    Serious side effects included bleeding, infections and irregular heartbeat, and some study participants developed a second type of cancer.

    acalabrutinibapprovalAstraZenecacancerchemotherapyDr Richard PazdurFood and Drug Administrationlymphoma drugNon-Hodgkin Lymphoma
    Source : AP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok